肥満:臨床的影響,病理生理学,合併症,治療戦略における近代的な革新

Mohammad Iftekhar Ullah¹, Sadeka Tamanna^1,2

¹Department of Medicine, University of Mississippi Medical Center, 2500 N State St., Jackson, MS 39216, USA.

Medicines (Basel, Switzerland)

|August 22, 2025

まとめ

GLP-1アゴニストのような新しい肥満薬は体重減少と健康上の利点がありますしかし,コスト,アクセス,および副作用は,政策改革と多分野的なケアを必要とする課題です.

科学分野:

内分泌学
代謝疾患
薬理学について

背景:

肥満は世界的な健康問題で 2型糖尿病や心血管疾患や癌を引き起こし経済的にも大きな影響を及ぼしています
以前の肥満治療薬は有効性が限られ,深刻な副作用があり,治療中止に至った.
肥満による世界的な経済的負担は毎年2兆ドルと推定されています

研究の目的:

肥満管理のためのインクレチンベースの治療法の変革の可能性を検討する.
肥満治療における課題を強調し,政策改革を提唱する.
多分野アプローチと将来の研究方向の必要性を強調する.

主な方法:

GLP-1受容体アゴニストと新興治療法の臨床試験データのレビュー
現在の肥満治療法と新しい肥満治療法の有効性,安全性,耐容性の分析
社会経済的な要因,アクセス障壁,長期的な成果の検討

主要な成果:

GLP-1受容体アゴニストは体重を大幅に減らし (15~25%) 心血管疾患とT2Dの発生率を減少させます.
新しい治療法により耐性や筋肉の保存が向上する見込みがあります
高額な費用,アクセスの問題,副作用が治療の普及を妨げています

結論:

インクレチンベースの治療法は肥満の管理に革命をもたらしかつてない効果をもたらします
費用,アクセス,長期的な安全性に対処するには政策改革と統合ケアが必要です
将来の研究は長期的成果に焦点を当ててサルコペニアのようなリスクを軽減しライフスタイル支援を促進すべきです

キーワード:

二重GIP/GLP-1アゴニスト GLP-1受容体アゴニスト新しい治療法メタボリックシンドローム肥満薬剤療法体重管理

さらに関連する動画

04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

620

10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.1K

関連する概念動画

01:24

Obesity

612

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

612

01:15

Diabetes: Management and Pharmacotherapy

362

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

362

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

01:29

Chronic Pancreatitis II: Collaborative Care

128

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

128

01:20

Pathophysiology of Diabetes

1.2K

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...